Rho Kinase Inhibition with Fasudil in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis—Symptomatic Treatment Potential after Disease Onset

Despite an improved understanding of the genetic background and the pathomechanisms of amyotrophic lateral sclerosis (ALS) no novel disease-modifying therapies have been successfully implemented in clinical routine. Riluzole still remains the only clinically approved substance in human ALS treatment...

全面介紹

Na minha lista:
書目詳細資料
發表在:Front Pharmacol
Main Authors: Günther, René, Balck, Alexander, Koch, Jan C., Nientiedt, Tobias, Sereda, Michael, Bähr, Mathias, Lingor, Paul, Tönges, Lars
格式: Artigo
語言:Inglês
出版: Frontiers Media S.A. 2017
主題:
Pharmacology
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5281550/
https://ncbi.nlm.nih.gov/pubmed/28197100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00017
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍